drugset / Trial / NCT00811252

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

NCT00811252

Phase 3 Completed 453 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of double-blind treatment in elderly patients.

Timeline

Start
2009-01
Primary completion
2010-02
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Vortioxetine Unknown 5 mg Oral